Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.72 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.72 |
| ▸ | ITGAL | P20701 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018206 | 1.00 | ITGB2 (0.72) | ITGB2ICAM1ITGAL | |
| SCHEMBL12802360 | 0.92 | ITGAL (0.61) | ITGB2ICAM1ITGAL | |
| SCHEMBL12802365 | 0.92 | ITGAL (0.61) | ITGB2ICAM1ITGAL | |
| SCHEMBL2390816 | 0.86 | ITGB2 (0.63) | ITGB2ICAM1ITGAL | |
| SCHEMBL2390810 | 0.86 | ITGB2 (0.63) | ITGB2ICAM1ITGAL | |
| SCHEMBL4016661 | 0.86 | ITGB2 (0.66) | ITGB2ICAM1ITGAL | |
| SCHEMBL4016665 | 0.86 | ITGB2 (0.66) | ITGB2ICAM1ITGAL | |
| SCHEMBL4476749 | 0.85 | ITGB2 (0.65) | ITGB2ICAM1ITGAL | |
| SCHEMBL4479764 | 0.85 | ITGB2 (0.65) | ITGB2ICAM1ITGAL | |
| SCHEMBL4479770 | 0.85 | ITGB2 (0.65) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589115-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7462637-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2--a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080090819-A1 | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-SULFONYLAMINO]-PROPIONAMIDE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7345074-B2 | Derivatives of [6,7-dihydro-5H-imidazol[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1560830-B1 | DERIVATIVES OF [6, 7-DIHYDRO-5H-IMIDAZO[1,2 - A]IMIDAZOLE -3 -SULFONYLAMINO]-PROPIONAMIDE AND THEIR USE AS INHIBITORS UPON THE INTERACTION OF CAMS AND LEUKOINTEGRINS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1712553-A2 | Derivates of [6, 7-dihydro - 5H - imidazo[1,2- alpha]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of CAMS and leukointegrins | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050165027-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050054704-A1 | Derivatives of [6,7-dihydro-5H- Imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | US | disclosed |
| US-20050054703-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | US | disclosed |
| US-6844360-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040127534-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127534-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | ARG1, ARG2, HPGDS | ITGB2 138/4885ICAM1 4/4885ITGAL 25/4885 |
| US-20080090819-A1 | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-SULFONYLAMINO]-PROPIONAMIDE | HPGDS, PTGIS, API5 | ITGB2 278/4885ICAM1 8/4885ITGAL 40/4885 |
| US-20050054704-A1 | Derivatives of [6,7-dihydro-5H- Imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | ARG1, HPGDS, MIF | ITGB2 700/4885ICAM1 4/4885ITGAL 152/4885 |
| US-20050054703-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | HPGDS, PTGIS, API5 | ITGB2 278/4885ICAM1 8/4885ITGAL 40/4885 |
| US-20050165027-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | HPGDS, PTGIS, API5 | ITGB2 278/4885ICAM1 8/4885ITGAL 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.